Connor Lawrie
President & COO
Heartland Veterinary Partners
Liz Allison
CEO
Tricoci
Liz Allison is the CEO of Tricoci, a modern beauty enterprise built around three distinct business units: Salon & Spa, MedSpa, and CPG Brand Incubation. Each business draws on Tricoci’s professional legacy while scaling through its own focused growth strategy.
With more than 20 years of experience transforming and scaling consumer businesses across beauty, retail, and wellness, Liz has held executive leadership roles at Milan Laser Hair Removal, Neiman Marcus Group, and JCPenney.
Since joining Tricoci in 2023, Liz has helped accelerate the brand’s evolution through talent investment, service expansion, the launch of Tricoci MedSpa, and the development of Nutrire, the company’s salon-born, science-backed haircare brand.
Liz holds a degree in accounting from the University of Iowa, has served on multiple advisory and organizational boards, and actively mentors rising female leaders in service, retail, and CPG.
Julia Croxen
Vice President of Strategy Consulting
Rock Health
Julia is Vice President of Strategy Consulting at Rock Health, where she advises enterprise healthcare organizations on digital health and innovation strategy. She brings particular expertise supporting life sciences and pharma companies, as well as growth-stage startups. Her work focuses on go-to-market planning, commercialization, and patient activation and engagement across digital health segments and therapeutic areas, including cardio-metabolic health and women’s health. Prior to Rock Health, Julia worked in life sciences strategy consulting, driving pipeline portfolio prioritization, launch planning, and lifecycle management initiatives for biopharma clients. She studied Neurobiology and Global Health and Health Policy at Harvard University.
Lauren Baker
Associate
Barnes & Thornburg
John Cox
Partner
Barnes & Thornburg
With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.
Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.
John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.
John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.